Merck initiates phase III fertility study with pergoveris in poor ovarian response patients
The ESPART phase III clinical study focuses on patients that respond poorly to attempts at ovarian stimulation
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.